These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16563946)

  • 1. Heart and kidney: fatal twins?
    Ritz E
    Am J Med; 2006 May; 119(5 Suppl 1):S31-9. PubMed ID: 16563946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
    Maione A; Nicolucci A; Craig JC; Tognoni G; Moschetta A; Palasciano G; Pugliese G; Procaccini DA; Gesualdo L; Pellegrini F; Strippoli GF;
    J Nephrol; 2007; 20(6):646-55. PubMed ID: 18046666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.
    Menne J; Chatzikyrkou C; Haller H
    J Hypertens; 2010 Oct; 28(10):1983-94. PubMed ID: 20634721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S; Lewis JB
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal disease: a common and a silent killer.
    de Zeeuw D
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S27-35. PubMed ID: 18580863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
    Barri YM; Palmer BF; Ram CV
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):34-45. PubMed ID: 19667709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
    Chrysant SG
    Clin Ther; 2008; 30 Pt 2():2181-90. PubMed ID: 19281913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes, nephropathy, and the renin system.
    Hollenberg NK
    J Hypertens Suppl; 2006 Mar; 24(1):S81-7. PubMed ID: 16601578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria in heart failure: what do we really know?
    Dobre D; Nimade S; de Zeeuw D
    Curr Opin Cardiol; 2009 Mar; 24(2):148-54. PubMed ID: 19532101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.